论文部分内容阅读
目的 :测定放射性碘13 1I治疗前后Graves病患者血清甲状腺球蛋白抗体 (TGA)、甲状腺微粒体抗体 (TMA) ,探讨放射性碘在Graves病治疗中的价值。方法 :应用放射免疫分析法 (RIA)对Graves病患者13 1I治疗前及治疗后 2 ,4,6 ,8,10及 12个月的血清TGA ,TMA水平进行动态测量。结果 :血清TGA水平在13 1I治疗后 2和 8个月 ,血清TMA水平在13 1I治疗后 10个月均出现显著降低 (P分别 <0 0 5 ;<0 0 1;<0 0 1)。13 1I治疗后两项抗体的阳性转阴率明显高于阴性转阳率。结论 :放射性碘13 1I治疗Graves病可以使甲状腺自身抗体水平降低 ,放射性碘疗法可以促进自身免疫状态的缓解和修复。
Objective: To determine the serum thyroglobulin antibody (TGA) and thyroid microsomal antibody (TMA) in patients with Graves’ disease before and after radioiodine 131I treatment, and discuss the value of radioactive iodine in the treatment of Graves disease. Methods: Radioimmunoassay (RIA) was used to measure the levels of serum TGA and TMA in patients with Graves disease before treatment with 131I and at 2, 4, 6, 8, 10 and 12 months after treatment. Results: Serum TGA levels at 2 and 8 months after 131I treatment were significantly lower in serum TMA levels at 10 months after 131I treatment (P <0 05; <0 01 and <0 01, respectively). The positive rates of the two antibodies after 1I treatment were significantly higher than those of the negative ones. CONCLUSION: Radioiodine 131I treatment of Graves’ disease can reduce the level of thyroid autoantibodies. Radioiodine therapy can promote the remission and repair of autoimmune state.